Advancing Aortic Research Through Global Collaboration

Research & Registry

Transforming scientific discovery into meaningful improvements in the diagnosis, management, and care of people with Heritable Thoracic Aortic Disease (HTAD) is central to MAC’s mission. By prioritizing knowledge translation, MAC ensures its research on HTAD reaches beyond academic journals to the clinicians, researchers, guideline committees, and families who need it most.

Our Ethos

The Montalcino Aortic Consortium (MAC) formed in 2013 around the need for international cooperation in the study of human diseases, largely determined by variation in genes, that affect the aorta and its major branches.

BUILDING KNOWLEDGE. IMPROVING CARE.

2,000+

Enrolled in the global MAC Registry

20+ Countries

Representation across six continents

20+ Clinical Centres

Advancing research and care

Research Publications

Browse peer-reviewed publications from MAC researchers advancing the science of Heritable Thoracic Aortic Disease.

Conferences

Stay informed about upcoming MAC meetings, scientific symposia, and international events bringing the HTAD community together.

Become MAC Member

Join a global network of clinicians and researchers shaping the future of HTAD care, research, and precision medicine.

Featured perspective

Dianna M. Milewicz, MD, PhD

Executive Chair & Principal
Investigator
Montalcino Aortic Consortium

For more than 25 years, Dr. Dianna Milewicz has led groundbreaking research into the genetic causes of aortic disease, helping transform the diagnosis, management, and prevention of Heritable Thoracic Aortic Disease (HTAD). In this featured perspective, Dr. Milewicz discusses how genetic discovery, collaborative research, and precision medicine are advancing patient care worldwide. She also shares the vision behind the MAC and its role in translating data into evidence-based care that helps prevent aortic dissections and save lives.